Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 18, 2026.

B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers

Jamie van Langelaar, Liza Rijvers, Joost Smolders and 1 more (opens in a new tab)

Frontiers in Immunology · 2020 · Review · CC BY

doi:10.3389/fimmu.2020.00760 (opens in a new tab)

Abstract

Historically, multiple sclerosis (MS) has been viewed as being primarily driven by T cells. However, the effective use of anti-CD20 treatment now also reveals an important role for B cells in MS patients. The results from this treatment put forward T-cell activation rather than antibody production by B cells as a driving force behind MS. The main question of how their interaction provokes both B and T cells to infiltrate the CNS and cause local pathology remains to be answered. In this review, we highlight key pathogenic events involving B and T cells that most likely contribute to the pathogenesis of MS. These include (1) peripheral escape of B cells from T cell-mediated control, (2) interaction of pathogenic B and T cells in secondary lymph nodes, and (3) reactivation of B and T cells accumulating in the CNS. We will focus on the functional programs of CNS-infiltrating lymphocyte subsets in MS patients and discuss how these are defined by mechanisms such as antigen presentation, co-stimulation and cytokine production in the periphery. Furthermore, the potential impact of genetic variants and viral triggers on candidate subsets will be debated in the context of MS.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 18, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

In multiple sclerosis (MS) patients, pathogenic lymphocytes are triggered in the periphery to infiltrate the central nervous system (CNS) and cause local inflammation and demyelination. Anti-CD20 therapy has recently been approved as a novel treatment modality for MS. Although this underscores the fact that B cells play a key role in MS, the exact triggers, subsets and effector mechanisms contributing to the disease course are incompletely understood. The impact of this therapy on the antigen-presenting rather than the antibody-producing function of B cells in MS indicates that their interaction with T cells is an important driver of the pathogenesis. Alterations in cytokine production, co-stimulation and antigen presentation most likely contribute to the development of pathogenic B and T cells that are prone to enter the CNS. Such mechanisms might be influenced by the interplay between genetic and environmental risk factors. The major HLA-DRB1∗1501 locus accounts for 30% of the overall risk and has been shown to promote B cell-mediated induction of brain-infiltrating T helper (Th) cells in MS patients. Besides for HLA-DRB1∗1501, other genetic risk variants that have been identified in the past decades also appear to potentiate B and Th cell activation, a feature that is shared amongst several autoimmune disorders. Furthermore, infectious triggers such as the Epstein-Barr virus (EBV) alter their function and reactivity in MS. The current view is that transmigration of lymphocyte subsets into the CNS signifies relapsing disease, while compartmentalized CNS inflammation, as seen during disease progression, seems to be driven by tissue-resident populations. Since there is a clear association of relapse occurrence and radiological disease activity early in MS with the severity of disability progression later in MS, it is crucial to understand what motivates these cells to invade the CNS and why these cells instigate local pathology in MS patients.

In this review, we will discuss which and how brain-infiltrating lymphocyte subsets can contribute to MS pathogenesis. These pathogenic events are characterized by: (1) peripheral escape of pathogenic B cells from T cell-mediated control, (2) mutual activation of pathogenic B and T cells within peripheral germinal centers, and (3) re-activation of infiltrating B and T cells within the CNS. We will use current knowledge to consider the extent to which genetic and viral triggers may drive these pathogenic events in MS.

Impaired T Cell-Mediated Control of Pathogenic B Cells in MS

B and T cells closely interact in secondary lymphoid organs to generate an optimal immune response against invading pathogens. Within follicles, B cells recognize antigens via the highly specific B-cell receptor (BCR), resulting in internalization, processing and presentation to T cells. This mechanism is unique and tightly coordinated involving five consecutive and interdependent steps: (1) B-cell receptor signaling, (2) actin remodeling, (3) endosomal formation and transport, (4) HLA class II synthesis and trafficking to specialized late endosomes (i.e., MIICs), and (5) antigen processing and loading onto HLA class II molecules for presentation to CD4+ Th cells. Through their interaction with Th cells, germinal center (GC)-dependent and -independent memory B cells are formed, a process that is governed by the strength of the HLA/peptide signal. GC B cells respond to interleukin (IL)-21-producing follicular Th (Tfh) cells to develop into class-switched (IgG+) subsets or antibody-producing plasmablasts/plasma cells. Memory B cells, in return, specifically trigger Th effector subsets that help CD8+ cytotoxic T cells (CTLs) to kill the infected cell. In MS, this crosstalk between B and T cells is likely disturbed, eventually causing pathogenic instead of protective immunity. This may already start during selection of naive autoreactive B cells in the periphery.

Normally, after removal of the majority of B-cell clones expressing polyreactive antibodies in the bone marrow (central tolerance), surviving autoreactive B cells are kept in check by peripheral tolerance checkpoints. In contrast to most other autoimmune diseases, only peripheral and not central B-cell tolerance checkpoints are defective in MS, which coincides with increased frequencies of naive polyreactive populations in the blood. Although the exact cause is currently unknown, the escape of pathogenic B cells from peripheral control may be related to (1) chronic T-cell stimulation and (2) T cell-intrinsic defects (see Figure 1).

Epstein-Barr virus is one of the most thoroughly investigated pathogens regarding T-cell responses in MS. Many theories have been proposed how EBV can influence MS pathogenesis. One hypothesis is that, due to the chronic nature of this infection, continuous antigen presentation by B cells leads to functionally impaired, so-called “exhausted” T cells. This, together with the impact of HLA and other risk alleles, may result in inappropriate T cell-mediated control of EBV-infected (pathogenic) B cells. Consistent with this, peripheral CD8+ CTLs show decreased responses to EBV and not to cytomegalovirus antigens during the MS course. EBV antigens can also induce IL-10-producing CD4+ T regulatory cells (Tregs) capable of suppressing effector T-cell responses to recall antigens, as seen for other persistent viral infections such as lymphocytic choriomeningitis virus. However, forkhead box P3 (FOXP3+) Tregs have also been described to control infections, suggesting that additional T cell-intrinsic defects are involved. For example, Treg populations that are enriched in MS patients produce increased levels of interferon gamma (IFN-γ), express reduced levels of FOXP3 and have defective suppressive activity in vitro. This is not only accompanied with less suppression of effector T cells, but possibly also with impaired removal of pathogenic B cells, as described for other autoimmune diseases. The direct impact of Tregs on B cells in MS patients is still unknown. Treg function may be altered by variation in IL2RA and IL7RA, two known MS risk loci. FOXP3 correlates with IL-2 receptor (IL-2R) as well as IL-7 receptor (IL-7R) expression in Tregs. It can thus be expected that IL2RA and IL7RA, but also BACH2 variants impair Treg development in MS. This may even influence FOXP3- and IL-2R-expressing CD8+ T cells, which can suppress pro-inflammatory CD4+ Th cells and are reduced in the blood during MS relapses.

Th Cells as Inducers of Pathogenic Memory B Cells

After their escape from peripheral tolerance checkpoints, naive B cells likely interact with Th cells in GCs to eventually develop into memory populations potentially capable of infiltrating the MS brain (Figure 1). Little is known about how peripheral effector Th cells mediate the development of such pathogenic B cells in MS patients. In GCs of autoimmune mice, autoreactive B cells are triggered by Tfh cells producing high levels of IFN-γ. IFN-γ induces the expression of the T-box transcription factor T-bet, which upregulates CXC chemokine receptor 3 (CXCR3), elicits IgG class switching and enhanced antiviral responsiveness of murine B cells. Recently, we found that B cells from MS patients preferentially develop into CXCR3+ populations that transmigrate into the CNS. The IFN-γ receptor (IFNGR) and downstream molecule signal transducer and activator of transcription (STAT)1 in B cells are major determinants of autoimmune GC formation in mice. After ligation of the IFNGR, STAT1 is phosphorylated, dimerizes and translocates into the nucleus to induce genes involved in GC responses, such as T-bet and B-cell lymphoma 6 (BCL-6). Although IFN-γ-stimulated B cells of MS patients show enhanced pro-inflammatory capacity, it is unclear whether alterations in the IFN-γ signaling pathway contribute to the development of T-bet+ B cells infiltrating the CNS. Interestingly, a missense SNP in IFNGR2 has been found in MS, which may alter their development. Another target gene of the IFN-γ pathway is IFI30, which encodes for the IFN-γ-inducible lysosomal thiol reductase (GILT) and is considered one of the causal risk variants in MS. GILT is a critical regulator of antigen processing for presentation by HLA class II molecules. Together, these findings point to T-bet-expressing B cells as potent antigen-presenting cells that are highly susceptible to triggering by IFN-γ-producing Th effector subsets in MS (Figure 2).

Epstein-Barr virus may be an additional player in the formation of T-bet-expressing B cells. In mice, persistent viral infections sustain the development of these types of B cells, in which T-bet enhances their ability to recognize viral and self-antigens. EBV is hypothesized to persist latently in pathogenic B cells and mimic T-cell help for further differentiation in GCs. During acute infection, EBV uses a series of latency programs that drive B cells toward a GC response in an antigen-independent manner. Latent membrane protein (LMP)2A and LMP1 resemble signals coming from the BCR and CD40 receptor. In addition to their regulation of GC responses independently of T-cell help, recent evidence implicates that LMP2A and LMP1 can synergize with BCR and CD40 signaling as well. Interestingly, downstream molecules of the BCR (e.g., Syk, CBL-B) and CD40 receptor (e.g., TRAF3) are genetic risk factors for MS, therefore potentially cooperating with these latent proteins to enhance pathogenic B-cell development (Figure 2). This is supported by the binding of LMP2A to Syk in B cells and their escape from deletion in GCs of transgenic mice. Alternatively, pathogenic B cells can be induced via pathogen-associated TLR9, which binds to unmethylated CpG DNA and further integrate with BCR, CD40, and cytokine signals. Moreover, pathogenic B-cell responses in systemic autoimmune diseases such as systemic lupus erythematosus are enhanced after IFN-γ and virus-mediated induction of the T-bet. In MS patients, TLR9 ligation is also a major trigger of pro-inflammatory B cells and crucial for the differentiation of T-bet-expressing IgG1+ B cells during IFN-γ- and CD40-dependent GC-like cultures in vitro. Thus, under influence of specific genetic factors, EBV might join forces with IFN-γ-producing Th cells to stimulate pathogenic (T-bet+) GC B cells both in a direct (via infection and persistence in pathogenic subsets) and indirect (via TLR7/9) fashion in MS (Figure 2).

B Cells as Inducers of Pathogenic Memory TH Cells

Synchronously, within peripheral GCs, T-bet-expressing memory B cells are ideal candidates to trigger IFN-γ-producing, CNS-infiltrating Th cells in MS (Figure 1). In both mice and humans, T-bet promotes the antigen-presenting cell function of B cells. This may be related to the impact of EBV infection on B cell-intrinsic processing and presentation of antigens such as myelin oligodendrocyte glycoprotein (MOG). The potent antigen-presenting cell function of B cells in MS patients is further reflected by the effective use of anti-CD20 therapy. This therapy does not affect antibody serum levels, but significantly reduces pro-inflammatory Th-cell responses in MS, both ex vivo and in vivo. CD20 was found to be enriched on IFN-γ-inducible T-bet-expressing IgG+ B cells in MS blood, pointing to this pathogenic subset as an important therapeutic target. Furthermore, genetic changes in HLA class II molecules, as well as costimulatory molecules [e.g., CD80 and CD86], may additionally enhance Th cell activation by such memory B cells (Figure 2). HLA class II expression on murine B cells was reported to be indispensable for EAE disease onset. The in silico evidence that autoimmunity-associated HLA class II molecules have an altered peptide-binding groove, together with the potential role of several minor risk variants in the HLA class II pathway [e.g., CIITA, CLEC16A, IFI30 (Figure 2)], insinuates that antigens are differently processed and presented by B cells. This is supported by the increased ability of memory B cells to trigger CNS-infiltrating Th cells in MS patients carrying HLA-DRB1∗1501. These CNS-infiltrating T cells induced by B cells showed features of both Th1 and Th17, therefore representing highly pathogenic subsets. Such subsets are characterized by master transcription factors T-bet and RORγt, of which the latter is involved in the co-expression of IL-17 and GM-CSF in mice but not in humans. GM-CSF is an emerging pro-inflammatory cytokine produced by Th cells in MS. Our group recently revealed that a Th subset producing high levels of IFN-γ and GM-CSF, but low levels of IL-17, termed Th17.1, plays a key role in driving early disease activity in MS patients. Proportions of Th17.1 cells were reduced in the blood and highly enriched in the CSF of rapid-onset MS patients. In addition, Th17.1 cells and not classical Th1 and Th17 cells accumulated in the blood of MS patients who clinically responded to natalizumab (anti-VLA-4 mAb). The increased pathogenicity of Th17.1 is further exemplified by their high levels of multidrug resistance, anti-apoptotic and cytotoxicity-associated genes ABCB1 (MDR1), FCMR (TOSO) and GZMB (granzyme B), respectively. Th17.1 cells also show pronounced expression of the IL-23 receptor (IL-23R), which is essential for maintaining the pathogenicity of Th17 cells during CNS autoimmunity. IL-23 signals through the IL-23R and IL-12 receptor beta chain (IL-12Rβ1), resulting in JAK2-mediated STAT3 and TYK2-mediated STAT4 phosphorylation, and thereby inducing RORγt and T-bet, respectively. IL-12RB1, TYK2, STAT3, and STAT4 are known genetic risk variants and thus may directly induce Th effector cells in MS (Figure 2). In addition to its potential effect on Tregs (see above), MS-associated risk variant IL-2RA enhances GM-CSF production by human Th effector cells. To confirm the influence of these and other risk loci on the induction of pathogenic Th cells such as Th17.1 in MS, functional studies need to be performed in the near future.

The increased pathogenicity of Th effector cells may additionally be skewed by IL-6-producing B cells, which have been shown to trigger autoimmune GC formation and EAE in mice. Blocking of IL-6 prevents the development of myelin-specific Th1 and Th17 cells in EAE. The IL-6-mediated resistance of pathogenic Th cells to Treg mediated suppression in MS further links to the abundant expression of anti-apoptotic gene FCMR in Th17.1. Intriguingly, B cell-derived GM-CSF can be an additional cytokine driving pathogenic Th cells in MS patients by inducing pro-inflammatory myeloid cells. Although the causal MS autoantigen is still unknown, previous work implies that B cell-mediated presentation of EBV antigens at least contributes to pathogenic Th-cell induction. As mentioned above, antiviral CD8+ CTLs can become exhausted during persistent viral infections. Normally, this mechanism is compensated by the presence of cytotoxic CD4+ Th cells, which keep these types of infections under control. Such Th populations have been associated with MS progression and are also formed after EBV infection, producing high levels of IFN-γ, IL-2, granzyme B, and perforin. Similarly, EBV- and myelin-reactive Th cells from MS patients produce high levels of IFN-γ and IL-2 and strongly respond to memory B cells presenting myelin peptides. These studies indicate that the involvement of EBV-infected B cells, especially those expressing T-bet (see section “Th Cells as Inducers of Pathogenic Memory B Cells”), in activating Th effector cells with cytotoxic potential deserves further attention in MS.

Mechanisms of Infiltration

Under normal physiological conditions, the CNS has been considered an immune privileged environment and consists of a limited number of lymphocytes that cross the blood brain barrier (BBB). However, the revelation of meningeal lymphatic structures emphasized the cross-talk between CNS and peripheral lymphocytes in secondary lymphoid organs. The choroid plexus has been identified as the main entry of memory cells into the CNS, which is in the case of T cells mostly mediated by CCR6. The normal human CSF, as is acquired from the arachnoid space by lumbar spinal taps, contains more CD4+ Th cells compared to CD8+ T cells with central memory characteristics. The arachnoid space is a continuum with the perivascular space surrounding penetrating arterial and venous structures into the parenchyma. Within the brain parenchyma, more CD8+ T cells than CD4+ Th cells are found, however, their numbers remain low and can be found virtually restricted to the perivascular space. These T cells display a phenotype mostly associated with non-circulating tissue resident memory T cells. The perivenular perivascular space has been argued to be the common drainage site of antigens mobilized with the glymphatics flow. The exact relationship between memory T cells in the subarachnoid and perivascular space has been poorly identified in terms of replenishment and clonal association.

The BBB is dysfunctional during the early phase of MS, resulting in or is due to local recruitment of pathogenic T and B cells. Differential expression of pro-inflammatory cytokines, chemokine receptors and integrins by infiltrating lymphocytes have been argued to mediate disruption of the BBB in MS. Myelin-reactive CCR6+ and not CCR6– memory Th cells from MS patients not only produce high levels of IL-17, but also IFN-γ and GM-CSF. Previous studies mainly focused on the migration of IL-17-producing CCR6+ Th cells through the choroid plexus in EAE and in vitro human brain endothelial cell layers in MS brain tissues. In our recent study, we subdivided these CCR6+ memory Th cells into distinct Th17 subsets and found that especially IFN-γ producing Th17.1 (CCR6+CXCR3+CCR4–) cells were capable of infiltrating the CNS, both in ex vivo autopsied brain tissues and in in vitro transmigration assays. The fact that Th17.1 cells have cytotoxic potential and strongly co-express IFN-γ with GM-CSF suggests that these cells are involved in disrupting the permeability of the BBB in MS. The impact of CXCR3 on their transmigration capacity is likely the result of binding to the chemokine ligand CXCL10, which is produced by brain endothelial cells and is abundant in the CSF of MS patients. Similar observations were made for CXCR3 (T-bet)+ B cells. CCR6 is also highly expressed on memory B-cell precursors within the Th cell-containing light zone of GCs, and on IFN-γ-producing CD8+ T cells infiltrating the MS brain. This implies that both populations are susceptible to enter the CNS of MS patients. In addition to chemokine receptors and pro-inflammatory cytokines, adhesion molecules such as activated leukocyte cell adhesion molecule (ALCAM) enhance transmigration of pathogenic B and T cell subsets. Furthermore, CXCR3 is co-expressed with integrin α4β1 (VLA-4), which allows both B- and T-cell populations to bind to vascular cell adhesion protein 1 (VCAM-1) on brain endothelial cells. This is supported by the reducing effects of VLA-4 inhibition on B- and Th17-cell infiltration into the CNS and disease susceptibility in EAE. Natalizumab, a monoclonal antibody against VLA-4, is used as an effective second-line treatment for MS. Discontinuation of this treatment often results in severe MS rebound effects. Hence, the peripheral entrapment of populations like Th17.1 and T-bet+ B cells in natalizumab-treated patients probably underlies the massive influx of blood cells causing these effects. The same is true for EBV-reactivated B cells, which are enriched in lesions from MS patients after natalizumab withdrawal. A previous gene network approach using several GWAS datasets further highlights the relevance of adhesion molecules on the BBB endothelium for the crossing of T and B cells, especially those affected by IFN-γ.

Local Organization and Impact

Both B and T cells accumulate in active white matter lesions of the MS brain. In diagnostic biopsy studies, T cell-dominated inflammation is a characteristic of all lesion-types observed. Also in post-mortem MS lesions, white matter MS lesions with active demyelination associate with an increase in T cell numbers. Although CD4+ Th cells are in general outnumbered by CD8+ CTLs in brain lesions as investigated in autopsy studies, their role as triggers of local pathology should not be overlooked in MS. This is consistent with the enrichment of CD4+ Th cells in white matter lesions with active demyelination. An abundant number of CD4+ Th cells were also visible in pre-active lesion sites, suggesting an involvement of these cells in the early stages of lesion formation. Additionally, it was demonstrated that in contrast to CD8+ CTLs, brain-associated CD4+ Th-cell clonotypes are reduced in MS blood, indicating specific recruitment (as described above) or, alternatively, clonal expansion in the CNS. Furthermore, dominant Th-cell clones were undetectable following reconstitution after autologous hematopoietic stem cell transplantation in MS patients, which was not seen for CD8+ T cells. Interestingly, T-cell clones are shared between CNS compartments within a patient, including CSF and anatomically separated brain lesions. This suggests that brain-infiltrating T cells bear similar reactivity against local (auto)antigens.

In subsets of MS autopsy cases with acute and relapsing remitting MS, B cells can also be found predominantly in the perivascular space in association with active white matter lesions. The role of these perivascular B cells, including T-bet+ B cells, could be to re-activate (infiltrating) pro-inflammatory CD4+ and CD8+ T cells to cause MS pathology (Figure 1). Identical B-cell clones have been found in different CNS compartments of MS patients, including the meninges. Within the meninges, B- and T cell-rich follicle-like structures have been found that localize next to cortical lesions, presumably mediating progressive loss of neurological function in MS. Interestingly, MS brain-infiltrating lymphocytes express and respond to IL-21, the cytokine that drives follicular T- and B-cell responses. Additionally, IFN-γ triggering of B cells promotes ectopic follicle formation in autoimmune mice, suggesting that the structures observed in the MS CNS are induced by B cells interacting with IFN-γ-producing T cells. However, the role of IL-17 in this process should not be ruled out, as shown in EAE.

Besides mediating migration and organization of pathogenic lymphocytes in the MS brain, cytokines are likely relevant effector molecules. IFN-γ production by Th cells also associates with the presence of demyelinating lesions in the CNS. IFN-γ, and possibly also GM-CSF, can activate microglia or infiltrated macrophages to cause damage to oligodendrocytes. As for B cells, increased production of TNF-α, IL-6, and GM-CSF has been found and we have recently shown that during Tfh-like cultures, IFN-γ drives IgG-producing plasmablasts in MS. One could speculate that after their re-activation by IFN-γ-producing Th cells within the meningeal follicles, T-bet+ memory B cells rapidly develop into antibody-producing plasmablasts/plasma cells (Figure 1). IFN-γ-induced GC formation promotes the generation of autoantibodies in lupus mice. The targeting of B cells and not plasmablasts/plasma cells by clinically effective anti-CD20 therapies in MS, as well as the abundance of oligoclonal bands in MS CSF, at least support the local differentiation of B cells into antibody-secreting cells. We argue that IgG secreted by local T-bet-expressing plasmablasts/plasma cells are highly reactive in the MS brain, although the (auto)antigen specificity and pathogenicity of such antibodies remain unclear in MS, as well as their contribution as effector molecules to MS pathology.

Several antigenic targets have been proposed to contribute to MS pathology. Next to myelin, which is one of the most intensively studied antigens, also EBV antigens are considered as major candidates. EBNA-1 specific IgG antibodies are predictive for early disease activity and are present in CSF from MS patients. Some studies imply that reactivated B cells in ectopic meningeal follicles cross-present EBV peptides to activate myelin- and EBNA-1 specific Th cells. Whether EBV is detected in the brain or solely recognized in the periphery and how this contributes to local pathology is still a matter of intense debate in the field. In addition to myelin and EBV, other antigenic targets of locally produced IgG and infiltrating T cells have been suggested, such as sperm-associated antigen 16 [SPAG16], neurofilament light, RAS guanyl-releasing protein 2 [RASGRP2], αB-crystallin and GDP-l-fucose synthase.

Concluding Remarks

In this review, we have discussed potential triggers and mechanisms through which interacting B and T cells drive the pathogenesis of MS. In our presented model, peripheral B cells escape from tolerance checkpoints as the result of impaired control by chronically exhausted or genetically altered regulatory T cells. Subsequently, B cells interact with IFN-γ-producing effector Th cells in germinal centers of lymphoid organs to create a feedforward loop, after which highly pathogenic subsets break through blood-CNS barriers and, together with infiltrating CD8+ CTLs are locally reactivated to cause MS pathology. Although definite proof is still lacking, these pathogenic events are likely mediated by an interplay between persistent infections such as EBV and genetic risk variants. Together, these factors may alter the selection, differentiation and pathogenic features of B- and T-cell subsets. In our view, more in-depth insights into how infections and genetic burden define the CNS-infiltrating potential and antigen specificity of such subsets should be the next step to take in the near future. The development of small molecule therapeutics against subsets driving the disease course would be an effective way of generating clinically relevant benefits without harmful effects in MS patients.

Author Contributions

JL, LR, and ML designed and wrote the manuscript. ML and JS revised the manuscript.

Conflict of Interest

JS received speaker/consultancy fee from Biogen, Merck, Novartis, and Sanofi-Genzyme. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 163

  1. 1.

    Hauser SL Waubant E Arnold DL Vollmer T Antel J Fox RJ B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med. (2008 ) 358:676–88.

    Not in our library10.1056/nejmoa0706383 (opens in a new tab)

  2. 2.

    Bar-Or A Calabresi PA Arnold D Markowitz C Shafer S Kasper LH Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. (2008 ) 63:395–400.

    Not in our library10.1002/ana.21363 (opens in a new tab)

  3. 3.

    Hauser SL Bar-Or A Comi G Giovannoni G Hartung H-P Hemmer B Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. (2016 ) 376:221–34.

    Not in our library10.1056/nejmoa1601277 (opens in a new tab)

  4. 4.

    Jelcic I Al Nimer F Wang J Lentsch V Planas R Jelcic I Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis. Cell. (2018 ) 175:85–100.e23.

    Not in our library10.1016/j.cell.2018.08.011 (opens in a new tab)

  5. 5.

    Morandi E Jagessar SA ‘t Hart BA Gran B. EBV infection empowers human B cells for autoimmunity: role of autophagy and relevance to multiple sclerosis. J Immunol. (2017 ) 199:435–48.

    Not in our library10.4049/jimmunol.1700178 (opens in a new tab)

  6. 6.

    Lunemann JD Jelcic I Roberts S Lutterotti A Tackenberg B Martin R EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med. (2008 ) 205:1763–73.

    Not in our library10.1084/jem.20072397 (opens in a new tab)

  7. 7.

    Farh KK Marson A Zhu J Kleinewietfeld M Housley WJ Beik S Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature. (2015 ) 518:337–43.

    Not in our library10.1038/nature13835 (opens in a new tab)

  8. 8.
    Defective T‐cell control of Epstein–Barr virus infection in multiple sclerosis · 2017
    Corrected
  9. 9.

    Bar-Or A Pender MP Khanna R Steinman L Hartung H-P Maniar T Epstein–Barr virus in multiple sclerosis: theory and emerging immunotherapies. Trends Mol Med. (2020 ) 26:296–310.

    Not in our library10.1016/j.molmed.2019.11.003 (opens in a new tab)

  10. 10.

    Machado-Santos J Saji E Troscher AR Paunovic M Liblau R Gabriely G The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain. (2018 ) 141:2066–82.

    Not in our library10.1093/brain/awy151 (opens in a new tab)

  11. 11.
    Tissue-resident memory T cells populate the human brain · 2018
    No notice
  12. 12.

    Rotstein D Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. (2019 ) 15:287–300.

    Not in our library10.1038/s41582-019-0170-8 (opens in a new tab)

  13. 13.

    Yuseff M-I Lennon-Duménil AM. B cells use conserved polarity cues to regulate their antigen processing and presentation functions. Front Immunol. (2015 ) 6:251.

    Not in our library10.3389/fimmu.2015.00251 (opens in a new tab)

  14. 14.

    Flora C Ronald NG. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol. (2006 ) 24:519–40.

    Not in our library10.1146/annurev.immunol.23.021704.115825 (opens in a new tab)

  15. 15.

    Kurosaki T Kometani K Ise W. Memory B cells. Nat Rev Immunol. (2015 ) 15:149.

    Not in our library10.1038/nri3802 (opens in a new tab)

  16. 16.

    Rawlings DJ Metzler G Wray-Dutra M Jackson SW. Altered B cell signalling in autoimmunity. Nat Rev Immunol. (2017 ) 17:421–36.

    Not in our library10.1038/nri.2017.24 (opens in a new tab)

  17. 17.

    Swain SL McKinstry KK Strutt TM. Expanding roles for CD4? T cells in immunity to viruses. Nat Rev Immunol. (2012 ) 12:136–48.

    Not in our library10.1038/nri3152 (opens in a new tab)

  18. 18.

    Kinnunen T Chamberlain N Morbach H Cantaert T Lynch M Preston-Hurlburt P Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest. (2013 ) 123:2737–41.

    Not in our library10.1172/jci68775 (opens in a new tab)

  19. 19.

    Samuels J Ng YS Coupillaud C Paget D Meffre E. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med. (2005 ) 201:1659–67.

    Not in our library10.1084/jem.20042321 (opens in a new tab)

  20. 20.

    Menard L Saadoun D Isnardi I Ng YS Meyers G Massad C The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest. (2011 ) 121:3635–44.

    Not in our library10.1172/jci45790 (opens in a new tab)

  21. 21.

    Cotzomi E Stathopoulos P Lee CS Ritchie AM Soltys JN Delmotte FR Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain. (2019 ) 142:1598–615.

    Not in our library10.1093/brain/awz106 (opens in a new tab)

  22. 22.

    Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol. (2003 ) 24:584–8.

    Not in our library10.1016/j.it.2003.09.005 (opens in a new tab)

  23. 23.

    The International Multiple Sclerosis Genetics Consortium, The Wellcome Trust Case Control Consortium, Sawcer S Hellenthal G Pirinen M Spencer CC Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. (2011 ) 476:214–9.

    Not in our library10.1038/nature10251 (opens in a new tab)

  24. 24.

    Marshall NA Vickers MA Barker RN. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J Immunol. (2003 ) 170:6183–9.

    Not in our library10.4049/jimmunol.170.12.6183 (opens in a new tab)

  25. 25.

    Brooks DG Trifilo MJ Edelmann KH Teyton L McGavern DB Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med. (2006 ) 12:1301–9.

    Not in our library10.1038/nm1492 (opens in a new tab)

  26. 26.

    Blackburn SD Wherry EJ. IL-10, T cell exhaustion and viral persistence. Trends Microbiol. (2007 ) 15:143–6.

    Not in our library10.1016/j.tim.2007.02.006 (opens in a new tab)

  27. 27.

    Voo KS Peng G Guo Z Fu T Li Y Frappier L Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation. Cancer Res. (2005 ) 65:1577–86.

    Not in our library10.1158/0008-5472.can-04-2552 (opens in a new tab)

  28. 28.

    Dominguez-Villar M Baecher-Allan CM Hafler DA. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat Med. (2011 ) 17:673–5.

    Not in our library10.1038/nm.2389 (opens in a new tab)

  29. 29.

    Viglietta V Baecher-Allan C Weiner HL Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. (2004 ) 199:971–9.

    Not in our library10.1084/jem.20031579 (opens in a new tab)

  30. 30.

    Kumar M Putzki N Limmroth V Remus R Lindemann M Knop D CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. J Neuroimmunol. (2006 ) 180:178–84.

    Not in our library10.1016/j.jneuroim.2006.08.003 (opens in a new tab)

  31. 31.

    Venken K Hellings N Broekmans T Hensen K Rummens JL Stinissen P. Natural naive CD4+CD25+CD127low regulatory T cell. (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J Immunol. (2008 ) 180:6411–20.

    Not in our library10.4049/jimmunol.180.9.6411 (opens in a new tab)

  32. 32.

    Kinnunen T Chamberlain N Morbach H Choi J Kim S Craft J Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood. (2013 ) 121:1595–603.

    Not in our library10.1182/blood-2012-09-457465 (opens in a new tab)

  33. 33.

    Hartmann FJ Khademi M Aram J Ammann S Kockum I Constantinescu C Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells. Nat Commun. (2014 ) 5:5056.

    Not in our library10.1038/ncomms6056 (opens in a new tab)

  34. 34.

    Kreft KL Verbraak E Wierenga-Wolf AF van Meurs M Oostra BA Laman JD Decreased systemic IL-7 and soluble IL-7Rα in multiple sclerosis patients. Genes Immunity. (2012 ) 13:587.

    Not in our library10.1038/gene.2012.34 (opens in a new tab)

  35. 35.

    Liu W Putnam AL Xu-yu Z Szot GL Lee MR Zhu S CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. (2006 ) 203:1701–11.

    Not in our library10.1084/jem.20060772 (opens in a new tab)

  36. 36.

    Roychoudhuri R Hirahara K Mousavi K Clever D Klebanoff CA Bonelli M BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature. (2013 ) 498:506–10.

    Not in our library10.1038/nature12199 (opens in a new tab)

  37. 37.

    Correale J Villa A. Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis. Ann Neurol. (2010 ) 67:625–38.

    Not in our library10.1002/ana.21944 (opens in a new tab)

  38. 38.

    Baughman EJ Mendoza JP Ortega SB Ayers CL Greenberg BM Frohman EM Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis. J Autoimmun. (2011 ) 36:115–24.

    Not in our library10.1016/j.jaut.2010.12.003 (opens in a new tab)

  39. 39.

    Correale J Villa A. Isolation and characterization of CD8+ regulatory T cells in multiple sclerosis. J Neuroimmunol. (2008 ) 195:121–34.

    Not in our library10.1016/j.jneuroim.2007.12.004 (opens in a new tab)

  40. 40.

    Frisullo G Nociti V Iorio R Plantone D Patanella AK Tonali PA CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients. Hum Immunol. (2010 ) 71:437–41.

    Not in our library10.1016/j.humimm.2010.01.024 (opens in a new tab)

  41. 41.

    Barnett BE Staupe RP Odorizzi PM Palko O Tomov VT Mahan AE Cutting Edge: B cell–intrinsic T-bet expression is required to control chronic viral infection. J Immunol. (2016 ) 197:1017–22.

    Not in our library10.4049/jimmunol.1500368 (opens in a new tab)

  42. 42.

    Rubtsova K Rubtsov AV van Dyk LF Kappler JW Marrack P. T-box transcription factor T-bet, a key player in a unique type of B-cell activation essential for effective viral clearance. Proc Natl Acad Sci USA. (2013 ) 110:E3216–24.

    Not in our library10.1073/pnas.1312348110 (opens in a new tab)

  43. 43.

    Peng SL Szabo SJ Glimcher LH. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci USA. (2002 ) 99:5545–50.

    Not in our library10.1073/pnas.082114899 (opens in a new tab)

  44. 44.

    van Langelaar J Rijvers L Janssen M Wierenga-Wolf AF Melief M-J Siepman TA Induction of brain-infiltrating T-bet–expressing B cells in multiple sclerosis. Ann Neurol. (2019 ) 86:264–78.

    Not in our library10.1002/ana.25508 (opens in a new tab)

  45. 45.

    Jackson SW Jacobs HM Arkatkar T Dam EM Scharping NE Kolhatkar NS B cell IFN-gamma receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6. J Exp Med. (2016 ) 213:733–50.

    Not in our library10.1084/jem.20151724 (opens in a new tab)

  46. 46.

    Domeier PP Chodisetti SB Soni C Schell SL Elias MJ Wong EB IFN-gamma receptor and STAT1 signaling in B cells are central to spontaneous germinal center formation and autoimmunity. J Exp Med. (2016 ) 213:715–32.

    Not in our library10.1084/jem.20151722 (opens in a new tab)

  47. 47.

    Dalpke AH Eckerle S Frey M Heeg K. Triggering of Toll-like receptors modulates IFN-γ signaling: involvement of serine 727 STAT1 phosphorylation and suppressors of cytokine signaling. Eur J Immunol. (2003 ) 33:1776–87.

    Not in our library10.1002/eji.200323621 (opens in a new tab)

  48. 48.

    Bar-Or A Fawaz L Fan B Darlington PJ Rieger A Ghorayeb C Abnormal B-cell cytokine responses a trigger of T-cell–mediated disease in MS? Ann Neurol. (2010 ) 67:452–61.

    Not in our library10.1002/ana.21939 (opens in a new tab)

  49. 49.

    Lill CM Luessi F Alcina A Sokolova EA Ugidos N de la Hera B Genome-wide significant association with seven novel multiple sclerosis risk loci. J Med Genet. (2015 ) 52:848–55.

    Not in our library10.1136/jmedgenet-2015-103442 (opens in a new tab)

  50. 50.

    Patsopoulos NA Baranzini SE Santaniello A Shoostari P Cotsapas C Wong G The multiple sclerosis genomic map: role of peripheral immune cells and resident microglia in susceptibility. bioRxiv[Preprint]. (2017 ).

    Not in our library10.1101/143933 (opens in a new tab)

  51. 51.

    Phipps-Yonas H Semik V Hastings KT. GILT expression in B cells diminishes cathepsin S steady-state protein expression and activity. Eur J Immunol. (2013 ) 43:65–74.

    Not in our library10.1002/eji.201242379 (opens in a new tab)

  52. 52.
    GILT: shaping the MHC class II-restricted peptidome and CD4+ T cell-mediated immunity · 2013
    Not checked
  53. 53.

    Hastings KT Lackman RL Cresswell P. Functional requirements for the lysosomal thiol reductase GILT in MHC class II-restricted antigen processing. J Immunol. (2006 ) 177:8569–77.

    Not in our library10.4049/jimmunol.177.12.8569 (opens in a new tab)

  54. 54.

    Rubtsov AV Rubtsova K Kappler JW Jacobelli J Friedman RS Marrack P. CD11c-expressing B cells are located at the T Cell/B cell border in spleen and are potent APCs. J Immunol. (2015 ) 195:71–9.

    Not in our library10.4049/jimmunol.1500055 (opens in a new tab)

  55. 55.

    Piovesan D Tempany J Pietro A. Di Baas I Yiannis C O’Donnell K c-Myb regulates the T-Bet-dependent differentiation program in B cells to coordinate antibody responses. Cell Rep. (2017 ) 19:461–70.

    Not in our library10.1016/j.celrep.2017.03.060 (opens in a new tab)

  56. 56.

    Pender MP. The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist. (2011 ) 17:351–67.

    Not in our library10.1177/1073858410381531 (opens in a new tab)

  57. 57.

    Tracy SI Kakalacheva K Lünemann JD Luzuriaga K Middeldorp J Thorley-Lawson DA. Persistence of Epstein-Barr virus in self-reactive memory B cells. J Virol. (2012 ) 86:12330–40.

    Not in our library10.1128/jvi.01699-12 (opens in a new tab)

  58. 58.

    Thorley-Lawson DA Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. (2004 ) 350:1328–37.

    Not in our library10.1056/nejmra032015 (opens in a new tab)

  59. 59.

    Roughan JE Thorley-Lawson DA. The intersection of Epstein-Barr virus with the germinal center. J Virol. (2009 ) 83:3968–76.

    Not in our library10.1128/jvi.02609-08 (opens in a new tab)

  60. 60.

    James T Linden M Morikawa H Fernandes SJ Ruhrmann S Huss M Impact of genetic risk loci for multiple sclerosis on expression of proximal genes in patients. Hum Mol Genet. (2018 ) 27:912–28.

    Not in our library10.1093/hmg/ddy001 (opens in a new tab)

  61. 61.

    Caldwell RG Wilson JB Anderson SJ Longnecker R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity. (1998 ) 9:405–11.

    Not in our library10.1016/s1074-7613(00)80623-8 (opens in a new tab)

  62. 62.

    Sindhava VJ Oropallo MA Moody K Naradikian M Higdon LE Zhou L A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens. J Clin Invest. (2017 ) 127:1651–63.

    Not in our library10.1172/jci89931 (opens in a new tab)

  63. 63.

    Jegerlehner A Maurer P Bessa J Hinton HJ Kopf M Bachmann MF. TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol. (2007 ) 178:2415–20.

    Not in our library10.4049/jimmunol.178.4.2415 (opens in a new tab)

  64. 64.

    Knox JJ Buggert M Kardava L Seaton KE Eller MA Canaday DH T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response. JCI Insight. (2017 ) 2:e92943.

    Not in our library10.1172/jci.insight.92943 (opens in a new tab)

  65. 65.

    Rubtsova K Rubtsov AV Thurman JM Mennona JM Kappler JW Marrack P. B cells expressing the transcription factor T-bet drive lupus-like autoimmunity. J Clin Invest. (2017 ) 127:1392–404.

    Not in our library10.1172/jci91250 (opens in a new tab)

  66. 66.

    Sawcer S Ban M Maranian M Yeo TW Compston A Kirby A A high-density screen for linkage in multiple sclerosis. Am J Hum Genet. (2005 ) 77:454–67.

    Not in our library10.1086/444547 (opens in a new tab)

  67. 67.

    Good-Jacobson KL Song E Anderson S Sharpe AH Shlomchik MJ. CD80 expression on B cells regulates murine T follicular helper development, germinal center B cell survival, and plasma cell generation. J Immunol. (2012 ) 188:4217–25.

    Not in our library10.4049/jimmunol.1102885 (opens in a new tab)

  68. 68.

    Smets I Fiddes B Garcia-Perez JE He D Mallants K Liao W Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells. Brain. (2018 ) 141:786–96.

    Not in our library10.1093/brain/awx372 (opens in a new tab)

  69. 69.

    Molnarfi N Schulze-Topphoff U Weber MS Patarroyo JC Prod’homme T Varrin-Doyer M MHC class II–dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med. (2013 ) 210:2921–37.

    Not in our library10.1084/jem.20130699 (opens in a new tab)

  70. 70.

    Parker Harp CR Archambault AS Sim J Ferris ST Mikesell RJ Koni PA B cell antigen presentation is sufficient to drive neuroinflammation in an animal model of multiple sclerosis. J Immunol. (2015 ) 194:5077–84.

    Not in our library10.4049/jimmunol.1402236 (opens in a new tab)

  71. 71.

    Raychaudhuri S Sandor C Stahl EA Freudenberg J Lee HS Jia X Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. (2012 ) 44:291–6.

    Not in our library10.1038/ng.1076 (opens in a new tab)

  72. 72.
    Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects · 2013
    No notice
  73. 73.

    Szabo SJ Kim ST Costa GL Zhang X Fathman CG Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. (2000 ) 100:655–69.

    Not in our library10.1016/s0092-8674(00)80702-3 (opens in a new tab)

  74. 74.

    Ivanov II McKenzie BS Zhou L Tadokoro CE Lepelley A Lafaille JJ The orphan nuclear receptor RORγt directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. (2006 ) 126:1121–33.

    Not in our library10.1016/j.cell.2006.07.035 (opens in a new tab)

  75. 75.

    Noster R Riedel R Mashreghi MF Radbruch H Harms L Haftmann C IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells. Sci Transl Med. (2014 ) 6:241ra80.

    Not in our library10.1126/scitranslmed.3008706 (opens in a new tab)

  76. 76.

    El-Behi M Ciric B Dai H Yan Y Cullimore M Safavi F The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol. (2011 ) 12:568–75.

    Not in our library10.1038/ni.2031 (opens in a new tab)

  77. 77.

    Galli E Hartmann FJ Schreiner B Ingelfinger F Arvaniti E Diebold M GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis. Nat Med. (2019 ) 25:1290–300.

    Not in our library10.1038/s41591-019-0521-4 (opens in a new tab)

  78. 78.

    van Langelaar J van der RM de Vries V Janssen M Wierenga-Wolf AF Spilt IM T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention. Brain. (2018 ) 141:1334–49.

    Not in our library10.1093/brain/awy069 (opens in a new tab)

  79. 79.

    Ramesh R Kozhaya L McKevitt K Djuretic IM Carlson TJ Quintero MA Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med. (2014 ) 211:89–104.

    Not in our library10.1084/jem.20130301 (opens in a new tab)

  80. 80.

    Cao Y Goods BA Raddassi K Nepom GT Kwok WW Love JC Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Sci Transl Med. (2015 ) 7:287ra74.

    Not in our library10.1126/scitranslmed.aaa8038 (opens in a new tab)

  81. 81.

    Acosta-Rodriguez EV Rivino L Geginat J Jarrossay D Gattorno M Lanzavecchia A Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. (2007 ) 8:639–46.

    Not in our library10.1038/ni1467 (opens in a new tab)

  82. 82.
    RBPJ Controls Development of Pathogenic Th17 Cells by Regulating IL-23 Receptor Expression · 2016
    Not checked
  83. 83.

    Teng MW Bowman EP McElwee JJ Smyth MJ Casanova JL Cooper AM IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. (2015 ) 21:719–29.

    Not in our library10.1038/nm.3895 (opens in a new tab)

  84. 84.

    Hussman JP Beecham AH Schmidt M Martin ER McCauley JL Vance JM GWAS analysis implicates NF-kappaB-mediated induction of inflammatory T cells in multiple sclerosis. Genes Immun. (2016 ) 17:305–12.

    Not in our library10.1038/gene.2016.23 (opens in a new tab)

  85. 85.

    Kimura A Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. (2010 ) 40:1830–5.

    Not in our library10.1002/eji.201040391 (opens in a new tab)

  86. 86.

    Zhou L Ivanov II Spolski R Min R Shenderov K Egawa T IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. (2007 ) 8:967–74.

    Not in our library10.1038/ni1488 (opens in a new tab)

  87. 87.

    Barr TA Shen P Brown S Lampropoulou V Roch T Lawrie S B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med. (2012 ) 209:1001–10.

    Not in our library10.1084/jem.20111675 (opens in a new tab)

  88. 88.

    Arkatkar T Du SW Jacobs HM Dam EM Hou B Buckner JH B cell–derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity. J Exp Med. (2017 ) 214:3207–17.

    Not in our library10.1084/jem.20170580 (opens in a new tab)

  89. 89.

    Serada S Fujimoto M Mihara M Koike N Ohsugi Y Nomura S IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. (2008 ) 105:9041–6.

    Not in our library10.1073/pnas.0802218105 (opens in a new tab)

  90. 90.

    Schneider A Long SA Cerosaletti K Ni CT Samuels P Kita M In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling. Sci Transl Med. (2013 ) 5:170ra15.

    Not in our library10.1126/scitranslmed.3004970 (opens in a new tab)

  91. 91.

    Neurath MF Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev. (2011 ) 22:83–9.

    Not in our library10.1016/j.cytogfr.2011.02.003 (opens in a new tab)

  92. 92.

    Gaublomme JT Yosef N Lee Y Gertner RS Yang LV Wu C Single-cell genomics unveils critical regulators of Th17 cell pathogenicity. Cell. (2015 ) 163:1400–12.

    Not in our library10.1016/j.cell.2015.11.009 (opens in a new tab)

  93. 93.

    Li R Rezk A Miyazaki Y Hilgenberg E Touil H Shen P Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med. (2015 ) 7:310ra166.

    Not in our library10.1126/scitranslmed.aab4176 (opens in a new tab)

  94. 94.

    Lünemann JD Kamradt T Martin R Münz C. Epstein-Barr Virus: environmental trigger of multiple sclerosis? J Virol. (2007 ) 81:6777–84.

    Not in our library10.1128/jvi.00153-07 (opens in a new tab)

  95. 95.
    CD4 CTL, a Cytotoxic Subset of CD4+ T Cells, Their Differentiation and Function · 2017
    No notice
  96. 96.

    Peeters LM Vanheusden M Somers V van Wijmeersch B Stinissen P Broux B Cytotoxic CD4+ T cells drive multiple sclerosis progression. Front Immunol. (2017 ) 8:1160.

    Not in our library10.3389/fimmu.2017.01160 (opens in a new tab)

  97. 97.

    Meckiff BJ Ladell K McLaren JE Ryan GB Leese AM James EA Primary ebv infection induces an acute wave of activated antigen-specific cytotoxic CD4+ T Cells. J Immunol. (2019 ) 203:1276–87.

    Not in our library10.4049/jimmunol.1900377 (opens in a new tab)

  98. 98.

    Lam JKP Hui KF Ning RJ Xu XQ Chan KH Chiang AKS. Emergence of CD4+ and CD8+ polyfunctional T cell responses against immunodominant lytic and latent EBV antigens in children with primary EBV infection. Front Microbiol. (2018 ) 9:416.

    Not in our library10.3389/fmicb.2018.00416 (opens in a new tab)

  99. 99.

    Harp CT Ireland S Davis LS Remington G Cassidy B Cravens PD Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol. (2010 ) 40:2942–56.

    Not in our library10.1002/eji.201040516 (opens in a new tab)

  100. 100.

    Broux B Markovic-Plese S Stinissen P Hellings N. Pathogenic features of CD4+CD28- T cells in immune disorders. Trends Mol Med. (2012 ) 18:446–53.

    Not in our library10.1016/j.molmed.2012.06.003 (opens in a new tab)

  101. 101.

    Herich S Schneider-Hohendorf T Rohlmann A Khaleghi GM Schulte-Mecklenbeck A Zondler L Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. Brain. (2019 ) 142:3411–27.

    Not in our library10.1093/brain/awz301 (opens in a new tab)

  102. 102.

    Hickey WF. Leukocyte traffic in the central nervous system: the participants and their roles. Semin Immunol. (1999 ) 11:125–37.

    Not in our library10.1006/smim.1999.0168 (opens in a new tab)

  103. 103.

    Louveau A Smirnov I Keyes TJ Eccles JD Rouhani SJ Peske JD Structural and functional features of central nervous system lymphatic vessels. Nature. (2015 ) 523:337–41.

    Not in our library10.1038/nature14432 (opens in a new tab)

  104. 104.

    Reboldi A Coisne C Baumjohann D Benvenuto F Bottinelli D Lira S C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol. (2009 ) 10:514–23.

    Not in our library10.1038/ni.1716 (opens in a new tab)

  105. 105.

    Ransohoff RM Kivisakk P Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol. (2003 ) 3:569–81.

    Not in our library10.1038/nri1130 (opens in a new tab)

  106. 106.

    de Graaf MT de Jongste AHC Kraan J Boonstra JG Smitt PAES Gratama JW. Flow cytometric characterization of cerebrospinal fluid cells. Cytometry B Clin Cytom. (2011 ) 80B:271–81.

    Not in our library10.1002/cyto.b.20603 (opens in a new tab)

  107. 107.

    Giunti D Borsellino G Benelli R Marchese M Capello E Valle MT Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. J Leukoc Biol. (2003 ) 73:584–90.

    Not in our library10.1189/jlb.1202598 (opens in a new tab)

  108. 108.

    Kivisakk P Trebst C Liu Z Tucky BH Sorensen TL Rudick RA T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. Clin Exp Immunol. (2002 ) 129:510–8.

    Not in our library10.1046/j.1365-2249.2002.01947.x (opens in a new tab)

  109. 109.

    Sorokin L. The impact of the extracellular matrix on inflammation. Nat Rev Immunol. (2010 ) 10:712–23.

    Not in our library10.1038/nri2852 (opens in a new tab)

  110. 110.

    Smolders J Remmerswaal EB Schuurman KG Melief J van Eden CG van Lier RA Characteristics of differentiated CD8(+) and CD4. (+) T cells present in the human brain. Acta Neuropathol. (2013 ) 126:525–35.

    Not in our library10.1007/s00401-013-1155-0 (opens in a new tab)

  111. 111.

    Plog BA Nedergaard M. The glymphatic system in central nervous system health and disease: past, present, and future. Annu Rev Pathol. (2018 ) 13:379–94.

    Not in our library10.1146/annurev-pathol-051217-111018 (opens in a new tab)

  112. 112.

    Dendrou CA Fugger L Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. (2015 ) 15:545.

    Not in our library10.1038/nri3871 (opens in a new tab)

  113. 113.

    Filippi M Bar-Or A Piehl F Preziosa P Solari A Vukusic S Multiple sclerosis. Nat Rev Dis Prim. (2018 ) 4:43.

    Not in our library10.1038/s41572-018-0041-4 (opens in a new tab)

  114. 114.

    Brucklacher-Waldert V Stuerner K Kolster M Wolthausen J Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain. (2009 ) 132:3329–41.

    Not in our library10.1093/brain/awp289 (opens in a new tab)

  115. 115.

    Cayrol R Wosik K Berard JL Dodelet-Devillers A Ifergan I Kebir H Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol. (2008 ) 9:137–45.

    Not in our library10.1038/ni1551 (opens in a new tab)

  116. 116.

    Rahman MT Ghosh C Hossain M Linfield D Rezaee F Janigro D IFN-γ, IL-17A, or zonulin rapidly increase the permeability of the blood-brain and small intestinal epithelial barriers: relevance for neuro-inflammatory diseases. Biochem Biophys Res Commun. (2018 ) 507:274–9.

    Not in our library10.1016/j.bbrc.2018.11.021 (opens in a new tab)

  117. 117.

    Subileau EA Rezaie P Davies HA Colyer FM Greenwood J Male DK Expression of chemokines and their receptors by human brain endothelium: implications for multiple sclerosis. J Neuropathol Exp Neurol. (2009 ) 68:227–40.

    Not in our library10.1097/nen.0b013e318197eca7 (opens in a new tab)

  118. 118.

    Sørensen TL Trebst C Kivisäkk P Klaege KL Majmudar A Ravid R Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J Neuroimmunol. (2002 ) 127:59–68.

    Not in our library10.1016/s0165-5728(02)00097-8 (opens in a new tab)

  119. 119.

    Suan D Krautler NJ Maag JLV Butt D Bourne K Hermes JR CCR6 defines memory B cell precursors in mouse and human germinal centers, revealing light-zone location and predominant low antigen affinity. Immunity. (2017 ) 47:1142–1153.e4.

    Not in our library10.1016/j.immuni.2017.11.022 (opens in a new tab)

  120. 120.

    Annibali V Ristori G Angelini DF Serafini B Mechelli R Cannoni S CD161(high)CD8+T cells bear pathogenetic potential in multiple sclerosis. Brain. (2011 ) 134(Pt 2):542–54.

    Not in our library10.1093/brain/awq354 (opens in a new tab)

  121. 121.

    Michel L Grasmuck C Charabati M Lécuyer M-A Zandee S Dhaeze T Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers. Sci Transl Med. (2019 ) 11:eaaw0475.

    Not in our library10.1126/scitranslmed.aaw0475 (opens in a new tab)

  122. 122.

    Lecuyer MA Saint-Laurent O Bourbonniere L Larouche S Larochelle C Michel L Dual role of ALCAM in neuroinflammation and blood-brain barrier homeostasis. Proc Natl Acad Sci USA. (2017 ) 114:E524–33.

    Not in our library10.1073/pnas.1614336114 (opens in a new tab)

  123. 123.

    Elices MJ Osborn L Takada Y Crouse C Luhowskyj S Hemler ME VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/Fibronectin binding site. Cell. (1990 ) 60:577–84.

    Not in our library10.1016/0092-8674(90)90661-w (opens in a new tab)

  124. 124.

    Lehmann-Horn K Sagan SA Bernard CC Sobel RA Zamvil SS. B-cell very late antigen-4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity. Ann Neurol. (2015 ) 77:902–8.

    Not in our library10.1002/ana.24387 (opens in a new tab)

  125. 125.

    Polman CH O’Connor PW Havrdova E Hutchinson M Kappos L Miller DH A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. (2006 ) 354:899–910.

    Not in our library10.1056/nejmoa044397 (opens in a new tab)

  126. 126.

    Sorensen PS Koch-Henriksen N Petersen T Ravnborg M Oturai A Sellebjerg F. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol. (2014 ) 261:1170–7.

    Not in our library10.1007/s00415-014-7325-8 (opens in a new tab)

  127. 127.

    Serafini B Scorsi E Rosicarelli B Rigau V Thouvenot E Aloisi F. Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal. J Neuroimmunol. (2017 ) 307:14–7.

    Not in our library10.1016/j.jneuroim.2017.03.013 (opens in a new tab)

  128. 128.

    Damotte V Guillot-Noel L Patsopoulos NA Madireddy L Behi M. El International Multiple Sclerosis Genetics Consortium A gene pathway analysis highlights the role of cellular adhesion molecules in multiple sclerosis susceptibility. Genes Immun. (2014 ) 15:126–32.

    Not in our library10.1038/gene.2013.70 (opens in a new tab)

  129. 129.

    Frischer JM Bramow S Dal-Bianco A Lucchinetti CF Rauschka H Schmidbauer M The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. (2009 ) 132(Pt 5):1175–89.

    Not in our library10.1093/brain/awp070 (opens in a new tab)

  130. 130.

    Lucchinetti C Bruck W Parisi J Scheithauer B Rodriguez M Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. (2000 ) 47:707–17.

    Not in our library10.1002/1531-8249(200006)47:63.0.co;2-q (opens in a new tab)

  131. 131.

    Ramaglia V Sheikh-Mohamed S Legg K Rojas OL Zandee S Fu F Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry. bioRxiv[Preprint]. (2019 ).

    Not in our library10.1101/638015 (opens in a new tab)

  132. 132.

    Planas R Metz I Martin R Sospedra M. Detailed characterization of T cell receptor repertoires in multiple sclerosis brain lesions. Front Immunol. (2018 ) 9:509.

    Not in our library10.3389/fimmu.2018.00509 (opens in a new tab)

  133. 133.

    Muraro PA Robins H Malhotra S Howell M Phippard D Desmarais C T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest. (2014 ) 124:1168–72.

    Not in our library10.1172/jci71691 (opens in a new tab)

  134. 134.

    Junker A Ivanidze J Malotka J Eiglmeier I Lassmann H Wekerle H Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain. (2007 ) 130:2789–99.

    Not in our library10.1093/brain/awm214 (opens in a new tab)

  135. 135.

    Planas R Santos R Tomas-Ojer P Cruciani C Lutterotti A Faigle W GDP-l-fucose synthase is a CD4+ T cell–specific autoantigen in DRB3∗02:02 patients with multiple sclerosis. Sci Transl Med. (2018 ) 10:eaat4301.

    Not in our library10.1126/scitranslmed.aat4301 (opens in a new tab)

  136. 136.

    Skulina C Schmidt S Dornmair K Babbe H Roers A Rajewsky K Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci USA. (2004 ) 101:2428–33.

    Not in our library10.1073/pnas.0308689100 (opens in a new tab)

  137. 137.
    Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients · 2017
    No notice
  138. 138.

    Stern JNH Yaari G Vander Heiden JA Church G Donahue WF Hintzen RQ B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Sci Transl Med. (2014 ) 6:107.

    Not in our library10.1126/scitranslmed.3008879 (opens in a new tab)

  139. 139.

    Lovato L Willis SN Rodig SJ Caron T Almendinger SE Howell OW Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain. (2011 ) 134:534–41.

    Not in our library10.1093/brain/awq350 (opens in a new tab)

  140. 140.

    Howell OW Reeves CA Nicholas R Carassiti D Radotra B Gentleman SM Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. (2011 ) 134(Pt 9):2755–71.

    Not in our library10.1093/brain/awr182 (opens in a new tab)

  141. 141.

    Magliozzi R Howell O Vora A Serafini B Nicholas R Puopolo M Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. (2007 ) 130:1089–104.

    Not in our library10.1093/brain/awm038 (opens in a new tab)

  142. 142.

    Tzartos JS Craner MJ Friese MA Jakobsen KB Newcombe J Esiri MM IL-21 and IL-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain. Am J Pathol. (2011 ) 178:794–802.

    Not in our library10.1016/j.ajpath.2010.10.043 (opens in a new tab)

  143. 143.

    Peters A Pitcher LA Sullivan JM Mitsdoerffer M Acton SE Franz B Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity. (2011 ) 35:986–96.

    Not in our library10.1016/j.immuni.2011.10.015 (opens in a new tab)

  144. 144.

    Olsson T. Cytokines in neuroinflammatory disease: role of myelin autoreactive T cell production of interferon-gamma. J Neuroimmunol. (1992 ) 40:211–8.

    Not in our library10.1016/0165-5728(92)90135-8 (opens in a new tab)

  145. 145.

    Renno T Lin J-Y Piccirillo C Antel J Owens T. Cytokine production by cells in cerebrospinal fluid during experimental allergic encephalomyelitis in SJL/J mice. J Neuroimmunol. (1994 ) 49:1–7.

    Not in our library10.1016/0165-5728(94)90174-0 (opens in a new tab)

  146. 146.

    Brosnan CF Cannella B Battistini L Raine CS. Cytokine localization in multiple sclerosis lesions. Correlation with adhesion molecule expression and reactive nitrogen species. Neurology. (1995 ) 45(6 Suppl. 6):S16–21.

    Not in our library10.1212/wnl.45.6_suppl_6.s16 (opens in a new tab)

  147. 147.

    Bsibsi M Peferoen LAN Holtman IR Nacken PJ Gerritsen WH Witte ME Demyelination during multiple sclerosis is associated with combined activation of microglia/macrophages by IFN-γ and alpha B-crystallin. Acta Neuropathol. (2014 ) 128:215–29.

    Not in our library10.1007/s00401-014-1317-8 (opens in a new tab)

  148. 148.

    Perry VH Holmes C. Microglial priming in neurodegenerative disease. Nat Rev Neurol. (2014 ) 10:217.

    Not in our library10.1038/nrneurol.2014.38 (opens in a new tab)

  149. 149.

    Li R Patterson KR Bar-Or A. Reassessing B cell contributions in multiple sclerosis. Nat Immunol. (2018 ) 19:696–707.

    Not in our library10.1038/s41590-018-0135-x (opens in a new tab)

  150. 150.

    Genain CP Cannella B Hauser SL Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med. (1999 ) 5:170–5.

    Not in our library10.1038/5532 (opens in a new tab)

  151. 151.

    Lunemann JD Tintore M Messmer B Strowig T Rovira A Perkal H Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol. (2010 ) 67:159–69.

    Not in our library10.1002/ana.21886 (opens in a new tab)

  152. 152.

    Rand KH Houck H Denslow ND Heilman KM. Epstein-Barr virus nuclear antigen-1. (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis. J Neurol Sci. (2000 ) 173:32–9.

    Not in our library10.1016/s0022-510x(99)00298-1 (opens in a new tab)

  153. 153.

    Castellazzi M Contini C Tamborino C Fasolo F Roversi G Seraceni S Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies. J Neuroinflamm. (2014 ) 11:188.

    Not in our library10.1186/s12974-014-0188-1 (opens in a new tab)

  154. 154.

    Serafini B Rosicarelli B Magliozzi R Stigliano E Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. (2004 ) 14:164–74.

    Not in our library10.1111/j.1750-3639.2004.tb00049.x (opens in a new tab)

  155. 155.

    Serafini B Rosicarelli B Franciotta D Magliozzi R Reynolds R Cinque P Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. (2007 ) 204:2899–912.

    Not in our library10.1084/jem.20071030 (opens in a new tab)

  156. 156.

    Sundström P Juto P Wadell G Hallmans G Svenningsson A Nyström L An altered immune response to Epstein-Barr virus in multiple sclerosis. A prospective study. Neurology. (2004 ) 62:2277–82.

    Not in our library10.1212/01.wnl.0000130496.51156.d7 (opens in a new tab)

  157. 157.

    Lang HLE Jacobsen H Ikemizu S Andersson C Harlos K Madsen L A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol. (2002 ) 3:940–3.

    Not in our library10.1038/ni835 (opens in a new tab)

  158. 158.

    Owens GP Bennett JL. Trigger, pathogen, or bystander: the complex nexus linking Epstein- Barr virus and multiple sclerosis. Mult Scler. (2012 ) 18:1204–8.

    Not in our library10.1177/1352458512448109 (opens in a new tab)

  159. 159.

    Willis SN Stadelmann C Rodig SJ Caron T Gattenloehner S Mallozzi SS Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain. (2009 ) 132(Pt 12):3318–28.

    Not in our library10.1093/brain/awp200 (opens in a new tab)

  160. 160.

    Sargsyan SA Shearer AJ Ritchie AM Burgoon MP Anderson S Hemmer B Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology. (2010 ) 74:1127–35.

    Not in our library10.1212/wnl.0b013e3181d865a1 (opens in a new tab)

  161. 161.

    Peferoen LA Lamers F Lodder LN Gerritsen WH Huitinga I Melief J Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain. (2010 ) 133:e137.

    Not in our library10.1093/brain/awp296 (opens in a new tab)

  162. 162.

    Aloisi F Serafini B Magliozzi R Howell OW Reynolds R. Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look. Brain. (2010 ) 133(Pt 12):e157.

    Not in our library10.1093/brain/awq223 (opens in a new tab)

  163. 163.

    de Bock L Fraussen J Villar LM Álvarez-Cermeño JC Van Wijmeersch B van Pesch V Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index. Eur J Neurol. (2016 ) 23:722–8.

    Not in our library10.1111/ene.12925 (opens in a new tab)

Cited by papers we hold 6

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.